

6 June 2014

Ms Kimberley Brown
Senior Adviser, Listings (Sydney)
ASX Compliance Pty Limited
20 Bridge Street
SYDNEY NSW 2000

(1 page by email)

Dear Ms Brown

I refer to your letter dated 6 June 2014 querying the increase in Biotron Limited's ('the Company') share price from a close of \$0.093 on 5 June 2014 to \$0.115 today, together with an increase in the volume of securities traded and provide the following response:

1. Is the Company aware of any information concerning it that has not been announced which, if known, could be an explanation for recent trading in the securities of the Company?

No.

2. If the answer to question 1 is yes, can an announcement be made immediately? If not, why not and when is it expected that an announcement will be made?

N/A.

3. Is there any other explanation that the Company may have for the price change and increase in volume in the securities of the Company?

No. The Company notes that an ASX announcement 'Presentation to Investors' was made on 27 May 2014 covering the Company's ongoing activities and as advised to the ASX on 23 May 2014 progress on the Phase 2 study (BIT225-008) of BIT 225, the Company's lead antiviral drug, remains on track to be fully recruited in mid-2014, with preliminary data available during the second half of the year.

4. Please confirm that the Company is in compliance with the listing rules and, in particular, listing rule 3.1.

The Company confirms that it is, to the best of its knowledge and belief, in compliance with the Listing Rules and in particular, Listing Rule 3.1.

Yours sincerely



Michelle Miller
Managing Director

pjn7747